正在进行的BREAKWATER试验正在评估Braftovi与Erbitux联合使用，加或不加化疗（mFOLFOX6），治疗携带BRAF V600E突变的初治转移性结直肠癌患者的效果。

BRAF V600E mutations are common in different tumor types (more frequently in melanomas, colon and thyroid carcinomas). BRAF Alterations in Brain Tumors: Different Diagnostic Relevance of BRAF ...

with a BRAF V600E mutation, as detected by an FDA-approved test. i The indication was approved based on a statistically significant and clinically meaningful improvement in response rate and ...

FDA approved Braftovi, Erbitux, and mFOLFOX6 for BRAF V600E mutation-positive metastatic colorectal cancer. BREAKWATER trial showed a 61% objective response rate for the treatment group versus 40% for ...

NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $149.5B and impressive gross profit margins of nearly 70%, announced today that the U.S. Food and ...

With today’s accelerated approval of the BRAFTOVI regimen, patients with metastatic colorectal cancer with a BRAF V600E mutation now have a first-line treatment option, which contains a targeted ...

(NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 ...